Raghavan Raghu, Howell Roger W, Zalutsky Michael R
Therataxis, LLC, JHU Eastern Complex, Suite B305, 1101 E. 33rd St., Baltimore MD 21218, United States of America.
Division of Radiation Research, Department of Radiology, New Jersey Medical School Cancer Center. Rutgers, The State Univeristy of New Jersey, 205 S. Orange Ave, Newark, NJ 07103, United States of America.
Biomed Phys Eng Express. 2017 Jun;3(3). doi: 10.1088/2057-1976/aa6db9. Epub 2017 May 5.
Radionuclides conjugated to molecules that bind specifically to cancer cells are of great interest as a means to increase the specificity of radiotherapy. Currently, the methods to disseminate these targeted radiotherapeutics have been either systemic delivery or by bolus injection into the tumor or tumor resection cavity. Herein we model a potentially more efficient method of delivery, namely pressure-driven fluid flow, called convection-enhanced delivery (CED), where a device infuses the molecules in solution (or suspension) directly into the tissue of interest. In particular, we focus on the setting of primary brain cancer after debulking surgery, where the tissue margins surrounding the surgical resection cavity are infiltrated with tumor cells and the most frequent sites of tumor recurrence. We develop the combination of fluid flow, chemical kinetics, and radiation dose models needed to examine such protocols. We focus on Auger electron-emitting radionuclides (e.g. Ga, Br, In, I, I, Pt, Pt) whose short range makes them ideal for targeted therapy in this setting of small foci of tumor spread within normal tissue. By solving these model equations, we confirm that a CED protocol is promising in allowing sufficient absorbed dose to destroy cancer cells with minimal absorbed dose to normal cells at clinically feasible activity levels. We also show that Auger emitters are ideal for this purpose while the longer range alpha particle emitters fail to meet criteria for effective therapy (as neither would energetic beta particle emitters). The model is used with simplified assumptions on the geometry and homogeneity of brain tissue to allow semi-analytic solutions to be displayed, and with the purpose of a first examination of this new delivery protocol proposed for radionuclide therapy. However, we emphasize that it is immediately extensible to personalized therapy treatment planning as we have previously shown for conventional CED, at the price of requiring a fully numerical computerized approach.
与特异性结合癌细胞的分子共轭的放射性核素作为提高放射治疗特异性的一种手段备受关注。目前,传播这些靶向放射治疗药物的方法要么是全身给药,要么是向肿瘤或肿瘤切除腔内进行大剂量注射。在此,我们模拟了一种可能更有效的给药方法,即压力驱动的流体流动,称为对流增强给药(CED),其中一种装置将溶液(或悬浮液)中的分子直接注入感兴趣的组织中。特别是,我们关注脑肿瘤切除术后原发性脑癌的情况,手术切除腔周围的组织边缘有肿瘤细胞浸润,且是肿瘤复发最常见的部位。我们开发了检查此类方案所需的流体流动、化学动力学和辐射剂量模型的组合。我们关注俄歇电子发射放射性核素(如Ga、Br、In、I、I、Pt、Pt),其短射程使其非常适合在正常组织内肿瘤小病灶扩散的这种情况下进行靶向治疗。通过求解这些模型方程,我们证实了CED方案有望在临床可行的活性水平下,以对正常细胞最小的吸收剂量实现足够的吸收剂量来破坏癌细胞。我们还表明,俄歇发射体非常适合此目的,而射程较长的α粒子发射体不符合有效治疗的标准(高能β粒子发射体也不符合)。该模型基于对脑组织几何形状和均匀性的简化假设使用,以显示半解析解,目的是首次检查为放射性核素治疗提出的这种新给药方案。然而,我们强调,正如我们之前对传统CED所展示的那样,它可以立即扩展到个性化治疗计划,代价是需要完全数值化的计算机方法。